The Dangers of Non-Nicotine E-Cigarettes and Vitamin Vaping

Aug.25.2022
The Dangers of Non-Nicotine E-Cigarettes and Vitamin Vaping
Non-nicotine e-cigarette health claims, including cancer prevention, asthma treatment, and improved energy, are unproven and may be unsafe. FDA warns.

In the trend of electronic cigarettes in recent years, some people have started inhaling nicotine-free "healthy" products that are believed to boost energy and have various health benefits, including cancer-fighting abilities, treatment of conditions such as asthma and ADHD, and even prevention of anemia. However, the US Food and Drug Administration (FDA) issued a warning in late 2021 regarding these products, stating that "these claims are unsubstantiated, the products may be ineffective, a waste of money, and unsafe.


Electronic cigarettes have received negative attention due to their potential health effects on young people, especially companies like JUUL that produce a variety of flavors specifically attractive to young people. Many of the concerns are similar for non-nicotine electronic cigarettes.


Doctor Jorge Mercado at Langone Medical Center at New York University, specializing in pulmonary medicine, stated, "Just because one way of taking vitamins is safe doesn't mean another method of absorption is safe. The lungs are not the primary organ for drug absorption.


There is still much unknown about how various substances are absorbed by the lungs and react with cells. General research on e-cigarettes tends to focus on the potential harmful effects of flavorings in e-cigarette products. These health impacts include cellular toxicity, or toxicity to cells, oxidative stress, and inflammation. In a study on e-cigarettes and flavored e-cigarettes, the highest level of active oxidative stress was produced by Vitamin Vape B12. The study also observed inflammation in lung epithelial cells and macrophages, which are white blood cells that identify and destroy microbes and dead cells.


The manufacturer of Vitamin Vape B12 also produces another e-cigarette related to Vitamin B12 called Breath B12. In December 2021, the US Food and Drug Administration issued a warning to Vitamin Vape saying "the use of your 'B12 VITAMINVAPE' product has raised safety concerns, as the ingredients or impurities in the orally inhaled product may cause laryngospasm or bronchospasm, toxic to tissue in the upper or lower respiratory tract, or may be absorbed and result in adverse systemic effects or organ toxicity.


Many health products, such as supplements and vitamins, are not regulated by the United States Food and Drug Administration, partly because they are not classified as food or drugs.


The FDA has stated that in this case, the product is considered a "new drug" and therefore requires approval from the FDA, which regulates it.


However, some damage may have already occurred. Vitamin Vape continues to sell its products and has 18,000 followers on Instagram. The US Food and Drug Administration has issued warning letters to other companies that offer similar products, including VitaCig, Eagle Energy, NV Nutrition, and VitaStik. These companies have been asked to correct any illegal actions. If they do not comply, the FDA may take enforcement action to prevent the products from reaching consumers.


Announcement:


This article has been compiled based on third-party information and is intended for industry professionals to exchange and learn from.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is solely for the purpose of professional exchange and research within the industry.


Due to limitations in the translator's abilities, the translated article may not accurately convey the original message. Please refer to the original article for accuracy.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related views and stances.


Copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
According to Reuters, citing Bloomberg News, British tobacco company Imperial Brands PLC plans to cut thousands of jobs across the United States and Europe as part of a cost reduction and organizational restructuring effort. The announcement drew market attention to the company’s shares. The move comes as global tobacco companies continue adjusting their operations amid slower cigarette market growth, changing consumer preferences and the transition toward next-generation nicotine products.
Aug.11
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s Victoria Steps Up Illegal Tobacco Enforcement With Store Closures and Penalties of Up to A$2.5 Million
Australia’s state of Victoria has activated new powers allowing Tobacco Licensing Victoria and police to shut premises suspected of selling, supplying or possessing illicit tobacco for up to 90 days. Longer closures can be ordered by a magistrates’ court. Businesses subject to closure orders must generally cease all trading and will be placed on a public list. Breaching a closure order can carry penalties of up to A$2.5 million and 20 years in prison.
Sep.10
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
PMI Global R&D Chief Meets Chinese Tobacco Regulator as China Advances Heated Cigarette Standards
PMI Global R&D Chief Meets Chinese Tobacco Regulator as China Advances Heated Cigarette Standards
Philip Morris International’s global R&D chief Michele Cattoni met Liu Sanjiang, deputy director of China’s State Tobacco Monopoly Administration, in Beijing on Aug. 27. The meeting comes as China advances mandatory standards for heated cigarettes and nicotine pouches, laying groundwork for their domestic introduction. Cattoni has held senior roles in PMI’s heated tobacco development, while China’s draft standard covers multiple heating architectures, including systems similar in principle to PMI’s IQOS ILUMA technology.
Aug.27